| 5.59 0.01 (0.18%) | 04-24 15:47 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Antares Pharma, Inc. operates as a specialized pharmaceutical enterprise, primarily dedicated to innovating and marketing medicines and advanced technologies. Its core mission is to address critical patient needs across a range of therapeutic areas. The company achieves this by developing, manufacturing, and commercializing groundbreaking therapeutic products, often leveraging its distinctive drug delivery systems. A significant portion of its product lineup involves injectable solutions. This includes XYOSTED, a subcutaneous therapy for testosterone replacement in adult men, and OTREXUP, an injectable methotrexate formulation used to manage severe active rheumatoid arthritis, active polyarticular juvenile idiopathic arthritis in children, and severe recalcitrant psoriasis in adults. While primarily known for its injectable portfolio, Antares also offers NOCDURNA sublingual tablets, prescribed for adults experiencing nocturia due to nocturnal polyuria, where they awaken multiple times nightly to urinate. Further expanding its therapeutic offerings, the company provides generic Epinephrine Injection USP for the urgent treatment of severe allergic reactions, including anaphylaxis, applicable to adults and certain pediatric patients. Other key products include Sumatriptan Injection USP for the acute management of migraine and cluster headaches in adults, and the Makena subcutaneous auto-injector, designed to lower the risk of preterm birth in women. Additionally, Antares markets Teriparatide injection for osteoporosis, addressing both postmenopausal women and men at heightened fracture risk, as well as those with glucocorticoid-induced osteoporosis. Beyond existing medications, Antares Pharma is actively involved in the development of various drug delivery devices, such as disposable pen injectors for diabetes and osteoporosis, and QuickShot auto-injectors. It is also advancing TLANDO for the treatment of testosterone deficiency in adult males, alongside other innovative drug/device combinations targeting urologic oncology, immunology, and endocrinology. The company has established strategic alliances and collaborative partnerships with prominent pharmaceutical entities like Pfizer Inc., Idorsia Pharmaceuticals Ltd, Teva Pharmaceutical Industries, Ltd, and AMAG. Founded in 1979 and headquartered in Ewing, New Jersey, Antares Pharma, Inc. transitioned into a subsidiary of Halozyme Therapeutics, Inc. as of May 23, 2022.
Wed, 13 Apr 2022
Antares Pharma to be acquired by Halozyme in $960M deal - The Business Journals
Wed, 13 Apr 2022
Halozyme to Acquire Antares Pharma to Create a Specialty Product and Drug Delivery Leader - PR Newswire
Wed, 13 Apr 2022
Halozyme acquires Antares Pharma for $960M to create drug delivery company - Drug Delivery Business
Wed, 13 Apr 2022
Antares Pharma Stock Soars After $960 Million Halozyme Buyout - Barron's
Mon, 24 Jan 2022
FDA Gives Fast Track Status to Firm for Adrenal Rescue Pen - Streetwise Reports
Wed, 15 Dec 2021
Antares Pharma Announces Divestiture of Otrexup® - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|